Panani Anna D
Critical Care Department, Medical School of Athens University, Epsilonvangelismos Hospital, Ipsilandou 45-47, Athens 106 76, Greece.
Ann Hematol. 2009 Apr;88(4):293-9. doi: 10.1007/s00277-008-0672-8. Epub 2009 Jan 7.
The occasional observation of constitutional chromosomal abnormalities in patients with a malignant disease has led to a number of studies on their potential role in cancer development. Investigations of families with hereditary cancers and constitutional chromosomal abnormalities have been key observations leading to the molecular identification of specific genes implicated in tumorigenesis. Large studies have been reported on the incidence of constitutional chromosomal aberrations in patients with hematologic malignancies, but they could not confirm an increased risk for hematologic malignancy among carriers of structural chromosomal changes. However, it is of particular interest that constitutional structural aberrations with breakpoints similar to leukemia-associated specific breakpoints have been reported in patients with hematologic malignancies. Because of insufficient data, it remains still unclear if these aberrations represent random events or are associated with malignancy. There has been a substantial discussion about mechanisms involved in constitutional structural chromosomal changes in the literature. The documentation of more patients with constitutional structural chromosomal changes could be of major importance. Most importantly, the molecular investigation of chromosomal regions involved in rearrangements could give useful information on the genetic events underlying constitutional anomalies, contributing to isolation of genes important in the development of the neoplastic process. Regarding constitutional anomalies in patients with hematologic disorders, a survey of the cytogenetic data of our cytogenetics unit is herein also presented.
在患有恶性疾病的患者中偶尔观察到染色体结构异常,这引发了一系列关于其在癌症发展中潜在作用的研究。对患有遗传性癌症和染色体结构异常的家族进行调查是关键观察点,从而在分子层面鉴定出与肿瘤发生相关的特定基因。已有大量关于血液系统恶性肿瘤患者染色体结构异常发生率的研究报道,但这些研究无法证实染色体结构改变携带者患血液系统恶性肿瘤的风险增加。然而,特别值得关注的是,在血液系统恶性肿瘤患者中已报道存在与白血病相关特定断点相似的染色体结构异常。由于数据不足,这些异常是随机事件还是与恶性肿瘤相关仍不清楚。文献中对染色体结构改变的机制进行了大量讨论。记录更多染色体结构改变的患者可能至关重要。最重要的是,对涉及重排的染色体区域进行分子研究可以提供有关染色体结构异常潜在遗传事件的有用信息,有助于分离出在肿瘤形成过程中起重要作用的基因。关于血液系统疾病患者的染色体结构异常,本文还展示了我们细胞遗传学部门的细胞遗传学数据调查情况。